Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients

BackgroundSmall cell lung cancer (SCLC) constitutes 15% of all lung cancer cases, with a comparatively low survival rate. The advent of immune checkpoint inhibitors (ICIs) has provided new alternatives for treating SCLC. However, the effectiveness of camrelizumab in the treatment of SCLC remains unc...

Full description

Bibliographic Details
Main Authors: Jizheng Tian, Lili Sui, Hong Wang, Xiaoyan Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Oncology
Subjects:
SCLC
camrelizumab
PD1 inhibitor
chemotherapy
case series
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1180735/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1180735/full

Similar Items